Qiagen (NYSE:QGEN) Stock Moved Down to Hold by DZ Bank

Qiagen (NYSE:QGEN) was downgraded by analysts at DZ Bank from a “strong-buy” rating to a “hold” rating in a report released on Thursday, Zacks reports.

Several other analysts have also commented on the company. Jefferies Financial Group reaffirmed a “buy” rating and set a $48.00 target price on shares of Qiagen in a report on Thursday, August 6th. Barclays set a $40.00 target price on shares of Qiagen and gave the company an “equal weight” rating in a report on Friday, August 7th. Robert W. Baird increased their price target on shares of Qiagen from $50.00 to $52.00 and gave the stock an “outperform” rating in a report on Thursday. Berenberg Bank set a $45.50 price target on shares of Qiagen and gave the company a “hold” rating in a research report on Tuesday, July 14th. Finally, Weiss Ratings raised shares of Qiagen from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, September 11th. Four equities research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $44.43.

Qiagen Trading Up 0.4%

QGEN opened at $50.42 on Thursday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.31 and a current ratio of 2.85. The stock’s 50 day moving average price is $44.44 and its 200-day moving average price is $40.64. The stock has a market cap of $10.39 billion, a price-to-earnings ratio of 20.73, a P/E/G ratio of 4.99 and a beta of 0.61. Qiagen has a one year low of $32.53 and a one year high of $57.81.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.60 by $0.02. Qiagen had a return on equity of 14.47% and a net margin of 19.49%. The business had revenue of $535.04 million for the quarter, compared to analyst estimates of $527.50 million. During the same period in the prior year, the company earned $0.60 earnings per share. The company’s revenue was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. On average, equities analysts forecast that Qiagen will post 2.44 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of QGEN. Hilltop National Bank acquired a new position in shares of Qiagen during the second quarter valued at approximately $50,000. Integrated Wealth Concepts LLC purchased a new position in Qiagen in the 2nd quarter valued at $59,000. Allworth Financial LP lifted its holdings in Qiagen by 20.8% in the 2nd quarter. Allworth Financial LP now owns 1,841 shares of the company’s stock valued at $72,000 after purchasing an additional 317 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in Qiagen by 46.8% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,746 shares of the company’s stock valued at $110,000 after purchasing an additional 876 shares in the last quarter. Finally, GAMMA Investing LLC boosted its stake in Qiagen by 70.4% during the 2nd quarter. GAMMA Investing LLC now owns 3,521 shares of the company’s stock worth $138,000 after purchasing an additional 1,455 shares during the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.

More Qiagen News

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Qiagen updated third-quarter 2026 guidance to adjusted EPS of $0.65 and revenue of $548 million, above consensus estimates of $0.62 and $534.1 million, respectively. The figures are consistent with the company’s preliminary results and signal better-than-expected operating performance.
• Positive Sentiment: EQT agreed to acquire Qiagen in an all-cash transaction valued at approximately $12.1 billion, offering €46.50 per share. The takeover provides a defined valuation and has been unanimously accepted, with the transaction nearing completion. Qiagen to Be Acquired by EQT for $12.1 Billion in All-Cash Deal
• Positive Sentiment: Robert W. Baird raised its price target to $52 from $50 and upgraded the stock to “outperform,” citing potential value near the takeover consideration. Robert W. Baird Qiagen rating
• Neutral Sentiment: Unusually heavy call-option activity suggests increased short-term trading interest, with call purchases roughly doubling typical volume, but it does not establish a fundamental change in valuation.
• Neutral Sentiment: JPMorgan reaffirmed its “neutral” rating while lowering its price target to $52 from $55, leaving limited projected upside relative to the current trading level. JPMorgan Qiagen rating
• Negative Sentiment: Law firms Brodsky & Smith and Halper Sadeh announced investigations into whether Qiagen obtained a fair price for shareholders. Such reviews could create deal uncertainty, although they do not currently indicate that the transaction will be blocked. Brodsky & Smith shareholder investigation

Qiagen Company Profile

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.